Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) CFO Christopher J. Senner sold 29,314 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the transaction, the chief financial officer now owns 779,607 shares in the company, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Exelixis Stock Performance
Shares of EXEL opened at $37.53 on Thursday. The firm has a market capitalization of $10.50 billion, a PE ratio of 21.20, a P/E/G ratio of 1.13 and a beta of 0.53. The stock has a 50 day simple moving average of $34.34 and a 200 day simple moving average of $31.50. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $37.64.
Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on EXEL. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. JMP Securities restated a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. Truist Financial lifted their price target on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.24.
Check Out Our Latest Report on EXEL
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Read More
- Five stocks we like better than Exelixis
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Buffett’s on the Sidelines – Should You Follow?
- What is a Dividend King?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Best Aerospace Stocks Investing
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.